Analysts Set OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Target Price at $5.67

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have earned a consensus recommendation of “Hold” from the five brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $5.6667.

Several research analysts recently weighed in on OKYO shares. HC Wainwright dropped their price target on OKYO Pharma from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, July 13th. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a research report on Friday, July 17th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OKYO. Citadel Advisors LLC acquired a new position in OKYO Pharma in the 3rd quarter valued at approximately $31,000. XTX Topco Ltd acquired a new stake in shares of OKYO Pharma during the 4th quarter valued at $36,000. Finally, Renaissance Technologies LLC grew its holdings in shares of OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after acquiring an additional 96,800 shares in the last quarter. 2.97% of the stock is owned by hedge funds and other institutional investors.

OKYO Pharma Stock Performance

OKYO opened at $1.52 on Monday. The stock has a fifty day moving average of $1.58 and a 200-day moving average of $1.75. OKYO Pharma has a 12-month low of $1.34 and a 12-month high of $3.35.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.